Literature DB >> 15691529

Hypoxia activates glycogen synthase kinase-3 in mouse brain in vivo: protection by mood stabilizers and imipramine.

Myoung-Sun Roh1, Tae-Yeon Eom, Anna A Zmijewska, Patrizia De Sarno, Kevin A Roth, Richard S Jope.   

Abstract

BACKGROUND: Glycogen synthase kinase-3 (GSK3), which is primarily regulated by an inhibitory phosphorylation of an N-terminal serine, has been implicated as contributing to mood disorders by the finding that it is inhibited by the mood stabilizer lithium.
METHODS: This study tested if the antidepressant imipramine or the mood stabilizers lithium and sodium valproate regulated pathophysiological serine-dephosphorylation of GSK3 caused by hypoxia in mouse brain in vivo.
RESULTS: Hypoxia caused rapid serine-dephosphorylation of both isoforms of GSK3, GSK3beta and GSK3alpha, in mouse cerebral cortex, hippocampus, and striatum. Pretreatment of mice with imipramine, sodium valproate, or lithium attenuated hypoxia-induced serine-dephosphorylation of GSK3beta and GSK3alpha in all three brain regions.
CONCLUSIONS: These results demonstrate that imipramine and mood stabilizers are capable of blocking pathophysiologically induced serine-dephosphorylation of GSK3, supporting the hypothesis that stabilization of serine-phosphorylation of GSK3 contributes to their therapeutic effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15691529     DOI: 10.1016/j.biopsych.2004.10.039

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  27 in total

Review 1.  The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways.

Authors:  Eléonore Beurel; Richard S Jope
Journal:  Prog Neurobiol       Date:  2006-08-28       Impact factor: 11.685

Review 2.  Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions.

Authors:  Richard S Jope; Myoung-Sun Roh
Journal:  Curr Drug Targets       Date:  2006-11       Impact factor: 3.465

Review 3.  Validating GSK3 as an in vivo target of lithium action.

Authors:  W Timothy O'Brien; Peter S Klein
Journal:  Biochem Soc Trans       Date:  2009-10       Impact factor: 5.407

4.  Antipsychotic-like effects of a neurotensin receptor type 1 agonist.

Authors:  Chelsea A Vadnie; Jennifer Ayers-Ringler; Alfredo Oliveros; Osama A Abulseoud; Sun Choi; Mario J Hitschfeld; Doo-Sup Choi
Journal:  Behav Brain Res       Date:  2016-02-22       Impact factor: 3.332

Review 5.  Neuroprotective action of lithium in disorders of the central nervous system.

Authors:  Chi-Tso Chiu; De-Maw Chuang
Journal:  Zhong Nan Da Xue Xue Bao Yi Xue Ban       Date:  2011-06

Review 6.  Neurotoxic saboteurs: straws that break the hippo's (hippocampus) back drive cognitive impairment and Alzheimer's Disease.

Authors:  Mak Adam Daulatzai
Journal:  Neurotox Res       Date:  2013-07-03       Impact factor: 3.911

7.  Possible association of the GSK3β gene with the anxiety symptoms of major depressive disorder and P300 waveform.

Authors:  Sha Liu; Ning Sun; Yong Xu; Chunxia Yang; Yan Ren; Zhifen Liu; Xiaohua Cao; Yan Sun; Qi Xu; Kerang Zhang; Yan Shen
Journal:  Genet Test Mol Biomarkers       Date:  2012-10-02

8.  Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder.

Authors:  Alessio Squassina; Mirko Manchia; Maria Del Zompo
Journal:  Hum Genomics Proteomics       Date:  2010-08-03

Review 9.  GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder.

Authors:  Michael K Rowe; Charlotte Wiest; De-Maw Chuang
Journal:  Neurosci Biobehav Rev       Date:  2007-03-15       Impact factor: 8.989

10.  Cocaine-induced hyperactivity and sensitization are dependent on GSK3.

Authors:  Jonathan S Miller; Ronald J Tallarida; Ellen M Unterwald
Journal:  Neuropharmacology       Date:  2009-03-27       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.